ImmunityBio, Inc. Reports Q2 2026 Results and Business Update

What Happened

• On August 4, 2026, ImmunityBio, Inc. announced a business update and reported its financial results for the three and six months ended June 30, 2026, and its financial position as of June 30, 2026. The company furnished the full press release as Exhibit 99.1 to the Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: August 4, 2026 (Form 8-K).
• Reporting periods: three- and six-month periods ended June 30, 2026; financial position as of June 30, 2026.
• Disclosure type: business update and quarterly financial results (press release furnished as Exhibit 99.1).

Why It Matters

• This filing makes ImmunityBio’s latest quarterly earnings, revenue and balance-sheet snapshot public. Retail investors should review the furnished press release (Exhibit 99.1) for the specific revenue, net income/loss, cash balance and operational updates that can affect the company’s near-term outlook and stock performance.